P E

Presse Ethypharm

Press

at Ethypharm

Contact

Ethypharm Group

Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible.

14/10/2021

Ethypharm consolidates its European presence with the integration of Altan, now led by Manuel Casegas as its General Manager

Saint-Cloud, France – October 14th, 2021 – Ethypharm is pleased to announce that it has successfully completed the acquisition of Altan and has now welcomed into the group all of its employees. Led by Manuel Casegas, this new affiliate gives Ethypharm a direct presence in Spain and expands its hospital injectables portfolio and R&D pipeline.  Ethypharm continues its ambitious growth strategy and consolidates its direct presence in Europe. With the integration of Altan, Ethypharm establishes itself in the fifth-largest pharmaceutical market in Europe and the eighth-largest market worldwide in terms of revenue. Ethypharm also benefits from an enlarged portfolio of high-quality hospital injectable products and a rich pipeline of R&D projects, which perfectly fit in the focus of the company.  To lead its new affiliate in Spain, Ethypharm has appointed Manuel Casegas as General Manager. “Given his role as Chief Industrial Officer of Altan over the past 3 years, Manuel Casegas knows very well Altan, its products and its teams. Ethypharm and Altan are highly complementary. In making this choice, we wanted to ensure business continuity. We trust that under Manuel’s leadership, Altan’s business will continue to grow and thrive, with an ambition higher than ever before.” comments Jean Monin, Chief Commercial Operations Officer of Ethypharm. Manuel Casegas graduated as a pharmacist from the University of Burgundy in France. After close to 20 years at Roche and Famar, he took over the responsibility of the industrial operations of Altan three years ago. “Integrating Ethypharm is a major milestone for Altan” said Manuel Casegas. “As Ethypharm’s General Manager in Spain, my first priority will be to ensure a rapid and smooth integration of Altan into Ethypharm so as to make the most of our combined strengths to serve health and patients.”  With this acquisition Ethypharm now has a full presence in the top 5 European markets and net sales of close to 400M€ (2020). About Ethypharm Ethypharm is a European pharmaceutical company focused on two areas: the Central Nervous System and Hospital injectables. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs 1,750 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80 IQVIA, Top 10 Pharmaceutical Markets Worldwide, 2020

Read more

25/08/2021

Prescriptions of medical cannabis dried flowers have started for patients included in the French pilot programme

St-Cloud, France, 25th August 2021 – The prescriptions of cannabis flowers to patients have started in France. The first batches provided by Aurora and distributed by Ethypharm are now available to the healthcare professionals of the first-ever French pilot program. Early 2021, Ethypharm and Aurora Europe announced their selection by the National Agency for the Safety of Medicines and Health Products (ANSM) as sole primary suppliers in the categories of medical cannabis dried flowers. Under the terms of the exclusive partnership, Aurora supplies the products and Ethypharm’s French subsidiary, Laboratoires Ethypharm, is responsible for pharmaceutical distribution. In a decree dated 7 October 2020, French authorities set the framework for a two-year pilot program of medical cannabis in France, which started earlier in 2021. Ethypharm and Aurora Europe were amongst the six producer-and-distributor tandems selected to provide medical cannabis products. They were nominated as the primary supplier for all the three lots they applied for (out of nine awarded) which are: Aurora 20/1 XPE (high-THC dried flowers), Aurora 8/8 XPE (THC: CBD balanced dried flowers) and Aurora 1/12 XPE (high-CBD dried flowers). Dried flowers are to be administrated with a vaporizer by STORZ & BICKEL, a well-known product tested and used by patients across Europe, recently selected by the ANSM. This solution was particularly expected to complement the other medical cannabis forms already made available in the pilot. With that solution in place, the Ethypharm-Aurora tandem is now able to provide the entire supply of medical cannabis dried flowers to French patients during the pilot program. Collaboration and partnerships are indeed part of Ethypharm’s DNA. By looking for the optimal partner in any country or region of the world, Ethypharm develops new ways to provide patients with the medical treatment they need. “Combining our pharmaceutical skills is, in our view, the right approach to build trust and confidence in medical cannabis for the long term in France. We want to be a driving force to support patients suffering from chronic pain when there is no other therapeutic option than medical cannabis. We are building the same type of cooperation in Germany with our partner Clever Leaves” declared Jean Monin, Chief Commercial Operations Officer of Ethypharm. “With its deep expertise in Central Nervous System disorders and experience in highly regulated medicines, Ethypharm is well prepared to collaborate with health authorities and physicians. If the pilot is positive, Ethypharm will, as a pharmaceutical company, secure distribution and access for the patient to the new option of therapeutic cannabis.“ The first batches of the three types of pharmaceutical quality pharmaceutical-grade medical cannabis dried flowers (THC dominant, balanced and CBD dominant) were delivered a few weeks ago to the French authorities. Aurora Nordic, production facility in Odense, Denmark Aurora’s European Good Manufacturing Practices EU-GMP certified by Danish Health Authorities, is committed to providing sufficient and consistent supply to patients and healthcare professionals as part of the pilot program. Up to 3,000 patients will benefit from the two-year trial led by ANSM. “Aurora’s participation in the French pilot program is a significant step toward providing better access to patients and will support the destigmatization of medical cannabis in France,” says Dr. Axel Gille, President of Aurora Europe. “Aurora has a proven track record of supporting the advancement of international medical cannabis markets alongside government bodies and with a deep commitment to compliance and excellence in the large-scale production of high-quality pharmaceutical grade medical cannabis. If successful, this pilot program could lead to one of the largest regulated markets for medical cannabis in Europe.” About Aurora Europe Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies pharmaceutical quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the market in Europe and today operates as one of the largest authorised producers and distributors of medical cannabis in Europe. Aurora’s internal network of EU GMP facilities continues to bring pharmaceutical quality, premium medical cannabis to patients worldwide, at the forefront in Europe with its facility Aurora Nordic in Odense, Denmark. For more information visit www.auroramedicine.com and follow us on LinkedIn. About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn. Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

Read more

18/06/2021

Health

Ethypharm to acquire Altan Pharma, entering the Spanish market and enhancing its Critical Care portfolio and R&D pipeline

Saint-Cloud, France – June 18th, 2021 – Ethypharm announces today that it has entered into a definitive agreement to acquire Altan Pharma, a specialty pharmaceutical company that develops, manufactures and markets injectable medicines for hospital use. Thanks to the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the top 5 European markets upon closing, which is expected in the second half of 2021. Ethypharm will also benefit from an enlarged portfolio of high quality hospital injectable products and a rich pipeline of R&D projects, which fit perfectly with its existing Critical Care franchise.   “Altan Pharma’s product portfolio and geographic coverage are highly complementary to those of Ethypharm. We look forward to welcoming Altan Pharma’s teams, as we are convinced that together, our product portfolio, our R&D and our industrial expertise, will put us in a stronger position to fulfil our commitment to the patients we serve”, said Bertrand Deluard, CEO of Ethypharm. “The Altan Pharma acquisition is an important milestone in Ethypharm’s transformation journey. By entering the Spanish market and reinforcing our Critical Care franchise, Ethypharm proves once again its ability to execute on its long-term growth ambition.”  “Joining an established European specialty pharmaceutical company, with a strong direct commercial presence in Europe beyond Spain and in major growth territories for injectable medicines, will be a booster for the international expansion of Altan Pharma’s product portfolio”  said Guillermo Herrera, CEO of Altan Pharma. “Since its inception in 1998, Altan Pharma has been committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers.” Jefferies International Limited acted as sole financial adviser to Altan Pharma on the transaction. About Altan Pharma Altan Pharma is a specialty pharmaceutical company that develops, manufactures and markets injectable medications for the hospital and other provider segments. Altan is a premier, global injectable drug company that is committed to improving patient care by providing specialty medications of superior quality and value for the benefit of patients and caregivers. Altan Pharma currently markets a portfolio of over 40 injectable medications used in pain and anaesthesia, epilepsy, oncology, anti-infectives, cardiovascular, and gynecology and is developing an attractive portfolio of additional products in these areas. Altan Pharma realised almost half of its 2020 sales through its own commercial operations in Spain, with the other half coming from the successful development of an international network of distributors and partners in more than 40 countries. Altan Pharma owns and operates two EU GMP manufacturing sites in Spain, located in Bernedo and Casarubios, which offer a wide range of injectable forms, including flexible plastic bags, liquid vials, lyophilized vials and ampoules. Circa 250 employees in R&D, manufacturing, market access, commercial and support functions make up the highly committed workforce of Altan Pharma. For more information, visit www.altanpharma.eu   About Ethypharm Ethypharm is a European pharmaceutical company focused on two therapeutic areas: the Central Nervous System and Critical Care. Ethypharm markets its drugs directly in Europe and China, and with partners in North America and the Middle East where its drugs are in high demand. The Group employs more than 1,500 people, mainly in Europe and China. Ethypharm works closely with authorities and healthcare professionals to ensure the appropriate use of and access to its medicines, by as many people as possible. For more information, visit www.ethypharm.com and follow us on LinkedIn   Media Relations Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

Read more

19/05/2021

Santé

Ethypharm renforce son pipeline de R&D en phase avancée avec un nouveau traitement de la crise de migraine

Saint-Cloud, France - Le 19 mai 2021 - Ethypharm annonce aujourd'hui avoir acquis les droits exclusifs pour le développement, l'enregistrement et la commercialisation pour les 5 premiers marchés européens d'une nouvelle formulation de célécoxib déjà approuvée aux Etats-Unis pour le traitement des crises de migraine aiguës.  La migraine est l'une des affections neurologiques les plus courantes, touchant environ 12 % de la population en Europe. De nombreux médicaments sont déjà disponibles pour la prise en charge des crises de migraine. Cependant, les patients ne sont pas toujours satisfaits de l'efficacité des traitements existants et certains peuvent s'inquiéter de leurs effets secondaires potentiels. Il y a donc un besoin de proposer des alternatives aux patients souffrant de crises de migraine aiguës. C’est cette logique qui a conduit, la société Dr Reddy’s à développer une nouvelle formulation liquide orale de l'anti-inflammatoire non stéroïdien célécoxib pour le marché américain et à mener des études pivots qui ont soutenu l'approbation de leur produit par la FDA américaine en mai 2020. Cet accord est stratégique pour les deux parties. En se concentrant sur le domaine de la douleur, Ethypharm avait depuis longtemps identifié le besoin d'offrir aux patients de nouvelles options de traitement pour la migraine aiguë. Du côté de Dr Reddy's, il était important de donner accès aux patients européens à ce dernier produit issu de son portefeuille de traitements contre la migraine aiguë. "Ethypharm possède l'expertise, l'excellence et la présence nécessaires en Europe ; c'est pourquoi nous avons conclu l'octroi à Ethypharm des droits de développement, d'enregistrement et de commercialisation de notre solution orale de célécoxib pour le Royaume-Uni et les marchés EU4 (Allemagne, Italie, France et Espagne), » a déclaré G B Ramesh Murthy, vice-président du développement commercial, produits de Dr Reddy’s. Il reste quelques étapes de développement avant de pouvoir enregistrer ce traitement en Europe. Le produit entre donc dans le pipeline de développement en phase avancée d'Ethypharm. Avec un marché européen des médicaments contre la migraine estimé à 550M€ en 2019, Ethypharm vise à obtenir rapidement les autorisations de mise sur le marché nécessaires pour pouvoir lancer ce traitement inédit au Royaume-Uni, en Allemagne, en France, en Italie et en Espagne. "Notre société s'est engagée à améliorer la vie des patients qui souffrent d'affections débilitantes du Système Nerveux Central. Le célécoxib dans cette formulation innovante offrira une nouvelle alternative aux patients qui souffrent de crises de migraine aiguës en Europe", a déclaré Frédéric Molin, Excecutive Vice-President Corporate Development d'Ethypharm. Il a également ajouté : " Au-delà de cet accord, Ethypharm offre une plateforme solide aux entreprises non européennes qui souhaitent maximiser le potentiel de leurs produits qui relèvent de nos domaines d'expertise. Nos équipes sont totalement ouvertes aux innovations externes et cherchent activement à engager des discussions avec d'autres partenaires. " A propos du Groupe Ethypharm Ethypharm est un laboratoire pharmaceutique européen spécialisé dans deux domaines thérapeutiques : le Système Nerveux Central et les Soins d’urgence. Ethypharm commercialise ses médicaments en direct en Europe et en Chine, et s’allie à des partenaires en Amérique du Nord et au Moyen-Orient où ses médicaments sont en forte demande. Le Groupe emploie plus de 1500 collaborateurs, majoritairement basés en Europe et en Chine. Ethypharm collabore étroitement avec les autorités et les professionnels de santé pour garantir l’utilisation appropriée et l’accès, au plus grand nombre, de ses médicaments. Pour plus d'informations sur Ethypharm, visitez le site www.ethypharm.com et suivez-nous sur LinkedIn. Contact média Mai Tran, presse@ethypharm.com, + 33 (0) 6 64 74 70 80

Read more